Ranbaxy, Dr. Reddy's To Benefit From Teva Skipping U.S. Lipitor Market
This article was originally published in PharmAsia News
Executive Summary
Ranbaxy Laboratories and Dr. Reddy's Laboratories can expect a greater share of the U.S. market for a generic of Pfizer Inc.'s Lipitor (atorvastatin) after Teva Pharmaceuticals said it would shun that market.